Pharmacotherapy and the maternal-fetal dyad: the use of medication during high-risk pregnancy and its impact on neonatal outcomes
High-Risk Pregnancy; Medication Adherence; Drug Safety; Pharmacoepidemiology; Pregnancy Outcome.
Background: Pharmacotherapy in high-risk pregnancy requires balancing maternal disease control, medication adherence and fetal safety. Objective: To investigate medication, use before and during pregnancy, potentially unsafe exposures, home medication non-adherence, and maternal and perinatal outcomes. Methods: Two prospective observational cohort analyses were conducted in a referral teaching maternity hospital in northeastern Brazil. The adherence study included 375 women assessed with the Morisky–Green–Levine scale; the medication-safety study included 376 women and classified pregnancy safety using Micromedex. Results: Non-adherence was observed in 68.0% and was associated with daily tablet burden (adjusted prevalence ratio 1.023; 95% CI 1.003–1.044), longer maternal hospital stay and a borderline association with maternal ICU admission. Medication use increased from 27.1% before pregnancy to 96.0% during pregnancy, while potentially unsafe exposure decreased from 13.6% to 4.5%. Older age and pre-existing hypertension were associated with gestational exposure. The association with congenital malformations (adjusted RR 4.13; 95% CI 1.18–14.45) was interpreted as an exploratory safety signal. Conclusion: Findings support preconception medication review, systematic adherence assessment and individualized pharmacotherapeutic care; causal inferences are not warranted.